These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 1976263)

  • 1. Regression estimation from grouped observations applied to structurally diverse D2-receptor antagonists.
    Mager PP; Rothe H
    Pharmazie; 1990 Jun; 45(6):424-33. PubMed ID: 1976263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor agonists and antagonists.
    Kohli JD
    Proc West Pharmacol Soc; 1990; 33():21-7. PubMed ID: 1980362
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
    Sesack SR; Bunney BS
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities and solid state conformation of monohydroxy-1,2,3,4,4a,5,10,10a-octahydrobenz[g]quinolines and its implications for a rotamer-based dopamine receptor model.
    Seiler MP; Markstein R; Walkinshaw MD; Boelsterli JJ
    Mol Pharmacol; 1989 May; 35(5):643-51. PubMed ID: 2566903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of four dopamine agonists on l-tetrahydropalmatine-induced analgesia and electroacupuncture analgesia in rabbits.
    Wu G; Jiang JW; Wu GC; Cao XD
    Zhongguo Yao Li Xue Bao; 1990 May; 11(3):196-200. PubMed ID: 1982393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3D QSAR study on a set of dopamine D4 receptor antagonists.
    Boström J; Böhm M; Gundertofte K; Klebe G
    J Chem Inf Comput Sci; 2003; 43(3):1020-7. PubMed ID: 12767161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Light modulates dopamine-regulated Walsh inhibitor activity and dopamine-dependent cyclic AMP accumulation in the rabbit retina.
    Nowak JZ; Zawilska J; Sek B; Schorderet M
    Pol J Pharmacol Pharm; 1990; 42(5):457-70. PubMed ID: 1983030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of N-(2-phenylethyl)-N-n-propyl-2-(3-hydroxyphenyl) ethylamine derivatives as dopamine receptor ligands.
    Claudi F; Cardellini M; Di Stefano A; Giorgioni G; Cantalamessa F; Renò F; Balduini W
    Drug Des Discov; 1994 Feb; 11(2):115-25. PubMed ID: 7915549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High affinity agonist binding to the dopamine D3 receptor: chimeric receptors delineate a role for intracellular domains.
    Robinson SW; Jarvie KR; Caron MG
    Mol Pharmacol; 1994 Aug; 46(2):352-6. PubMed ID: 7915820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptors labelled by PHNO.
    Seeman P; Ulpian C; Larsen RD; Anderson PS
    Synapse; 1993 Aug; 14(4):254-62. PubMed ID: 7902615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and dopaminergic features of six novel 3-arylpiperidines.
    Kostic-Rajacic A; Soskic V; Joksimovic J
    Boll Chim Farm; 1998 Nov; 137(10):417-21. PubMed ID: 10025971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of mixed D2/5-HT1A activity of N-heteroarylmethyl-N-phenylpiperazines, N-heteroarylethyl-N-phenylpiperazines and N-heteroarylpropyl-N-phenylpiperazines.
    Roglić G; Dukić-Stefanović S; Andrić D; Kostić-Rajacić S; Soskić V
    Pharmazie; 2001 Oct; 56(10):803-7. PubMed ID: 11683128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The peripheral dopaminergic system: morphological analysis, functional and clinical applications.
    Amenta F; Ricci A; Tayebati SK; Zaccheo D
    Ital J Anat Embryol; 2002; 107(3):145-67. PubMed ID: 12437142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens.
    Rouillon C; Degoulet M; Chevallier K; Abraini JH; David HN
    Brain Res; 2008 Mar; 1198():44-54. PubMed ID: 18261716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of dopamine D1 and D2 receptor agonists on inositol phosphate turnover in rat striatal slices.
    Gupta SK; Mishra RK
    Biochem Int; 1990 Dec; 22(5):887-94. PubMed ID: 1983069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland.
    Wreggett KA; De Léan A
    Mol Pharmacol; 1984 Sep; 26(2):214-27. PubMed ID: 6237254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.
    Hamacher A; Weigt M; Wiese M; Hoefgen B; Lehmann J; Kassack MU
    BMC Pharmacol; 2006 Sep; 6():11. PubMed ID: 16978403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.